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Abstract
Background: Genome-wide association studies identified a PTGER4 expression-modulating region on chromosome 5p13.1
as Crohn’s disease (CD) susceptibility region. The study aim was to test this association in a large cohort of patients with
inflammatory bowel disease (IBD) and to elucidate genotypic and phenotypic interactions with other IBD genes.
Methodology/Principal Findings: A total of 7073 patients and controls were genotyped: 844 CD and 471 patients with
ulcerative colitis and 1488 controls were analyzed for the single nucleotide polymorphisms (SNPs) rs4495224 and rs7720838
on chromosome 5p13.1. The study included two replication cohorts of North American (CD: n=684; controls: n=1440) and
of German origin (CD: n=1098; controls: n=1048). Genotype-phenotype, epistasis and transcription factor binding analyses
were performed. In the discovery cohort, an association of rs4495224 (p=4.10610
25; 0.76 [0.67–0.87]) and of rs7720838
(p=6.91610
24; 0.81 [0.71–0.91]) with susceptibility to CD was demonstrated. These associations were confirmed in both
replication cohorts. In silico analysis predicted rs4495224 and rs7720838 as essential parts of binding sites for the
transcription factors NF-kB and XBP1 with higher binding scores for carriers of the CD risk alleles, providing an explanation
of how these SNPs might contribute to increased PTGER4 expression. There was no association of the PTGER4 SNPs with IBD
phenotypes. Epistasis detected between 5p13.1 and ATG16L1 for CD susceptibility in the discovery cohort (p=5.99610
27 for
rs7720838 and rs2241880) could not be replicated in both replication cohorts arguing against a major role of this gene-gene
interaction in the susceptibility to CD.
Conclusions/Significance: We confirmed 5p13.1 as a major CD susceptibility locus and demonstrate by in silico analysis
rs4495224 and rs7720838 as part of binding sites for NF-kB and XBP1. Further functional studies are necessary to confirm
the results of our in silico analysis and to analyze if changes in PTGER4 expression modulate CD susceptibility.
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Crohn’s disease (CD) and ulcerative colitis (UC) are chronic
inflammatory bowel diseases (IBD) characterized by a complex
molecular pathogenesis resulting in an exaggerated immune
response and mucosal destruction [1–3]. Recent insights in the
interaction of various susceptibility genes with intestinal bacteria
have substantially helped to unravel the pathogenesis of IBD [2,4].
Since the identification of NOD2 as the first susceptibility gene for
CD in 2001 [5,6], various studies including genome-wide
association studies (GWAS) based on high-density SNP (single
nucleotide polymorphism) arrays have identified CD-associated
genetic variants of proteins involved in immune response,
autophagy or bacterial recognition, such as IL23R [7,8], ATG16L1
[9–11], and IRGM [12]. In addition, genotype-phenotype analysis
by us and others also demonstrated significant associations for
certain gene variants with particular CD phenotypes [13–20].
In 2007, a GWAS analyzing more than 318,000 SNPs identified
a 250 kb region on chromosome 5p13.1 contributing to CD
susceptibility [21]. The disease-associated alleles were found to
correlate with expression levels of the prostaglandin receptor EP4,
which binds prostaglandin E2 (PGE2) and is encoded by PTGER4,
the gene located closest to the associated region [21]. Since
Ptger4
2/2 mice develop severe dextran sodium sulphate (DSS)-
induced colitis while treatment with EP4-selective agonists has
protective effects against colitis through enhancement of epithe-
lium survival and regeneration, PTGER4 represents an attractive
IBD candidate gene [22–24]. Prostaglandins are arachidonic acid
metabolites produced by the action of the enzymes cyclooxygenase
(COX)-1 and -2 and play a crucial role in the regulation of
gastrointestinal homeostasis and IBD pathogenesis [25–27]. The
novel 5p13.1 CD susceptibility locus in proximity of PTGER4 was
also replicated by a recent genome-wide association study [28].
Moreover, the data on the disease-modifying effect of this region
on UC is very limited so far. In a recent GWAS of UC [29], a
significant association between rs4613763 variant in the 5p13
region and UC has been reported. To analyze the effect of SNPs
in the 5p13.1 region on IBD susceptibility in the German
population, a large study was initiated and genomic DNA of
2803 individuals was genotyped for the two SNPs rs4495224 and
rs7720838, identified in the initial study by Libioulle and co-
workers as CD susceptibility locus [21]. Although other SNPs in
the study by Libioulle et al. [21] showed moderately stronger
association with CD, these two SNPs were selected for genotyping
since they were both strongly associated with CD and showed the
most significant effect on PTGER4 expression in that GWAS. In
addition, the detailed phenotypic consequences of these gene
variants in CD and UC were here analyzed for the first time.
Moreover, we aimed to identify whether rs4495224 and
rs7720838 are part of potential binding sites for transcription
factors that might influence PTGER4 expression. As 5p13.1 may
also interact with other IBD susceptibility genes, a detailed analysis
for potential epistasis with the previously identified major CD
susceptibility gene variants (in NOD2, IL23R, ATG16L1 and in
SLC22A4/5 in the IBD5 region) was performed.
Methods
Ethics statement
This study was approved by the Ethics committee of the
Medical Faculty of Ludwig-Maximilians-University Munich (dis-
covery cohort), the University Hospital of the Christian-Albrechts-
University Kiel (German replication cohort), the Cleveland Clinic
and the University of Pittsburgh (North American replication
cohort). Written, informed consent was obtained from all patients
prior to genotyping and inclusion into the study. In the case of
minors, the consent was provided by the parents. The study
protocol adhered to the ethical principles for medical research
involving human subjects of the Helsinki Declaration (as described
in detail under: http://www.wma.net/en/30publications/
10policies/b3/index.html).
Study population and disease phenotype analysis
Overall, the German discovery study population (n=2803)
included 1315 IBD patients of Caucasian origin consisting of 844
patients with CD, 471 patients with UC, and 1488 healthy,
unrelated controls. In order to replicate the association of
chromosome 5p13.1 SNPs, a U.S. American Caucasian CD
cohort (CD: n=684; controls: n=1440) from the University of
Pittsburgh and the Cleveland Clinic and an additional German
replication cohort from the University Hospital of Schleswig-
Holstein at Kiel (CD: n=1098; controls: n=1048) were investi-
gated. The diagnosis of CD or UC was based on established
guidelines including endoscopic, radiological, and histopatholog-
ical criteria [30]. Patients with CD were assessed according to the
Montreal classification [31] analyzing age at diagnosis (A), location
(L), and behavior (B) of disease. In patients with UC, anatomic
location was also assessed in accordance to the Montreal
classification, using the criteria ulcerative proctitis (E1), left-sided
UC (distal UC; E2), and extensive UC (pancolitis; E3). Patients
with indeterminate colitis were excluded from the study. Pheno-
typic characteristics were collected blind to the results of the
genotypic data and included demographic and clinical parameters
(behavior and anatomic location of IBD, disease-related compli-
cations, surgical or immunosuppressive therapy) which were
recorded by analysis of patient charts and a detailed questionnaire
including an interview at time of enrolment. The demographic
Table 1. Demographic characteristics of the German IBD
discovery study population.
Crohn’s disease Ulcerative colitis Controls
n=844 n=471 n=1488
Gender
Male (%) 51.4% 52.1% 62.9%
Age (yrs)
Mean 6 SD 39.5613.1 41.8614.5 45.9610.7
Range 10–80 7–85 18–71
Body mass index
Mean 6 SD 23.164.2 23.964.2
Range 13–40 15–41
Age at diagnosis
(yrs)
Mean 6 SD 27.7611.7 32.0613.4
Range 1–78 9–81
Disease duration
(yrs)
Mean 6 SD 11.868.5 10.467.8
Range 0–44 1–40
Positive family
history of IBD
(%)
16.0% 16.1%
doi:10.1371/journal.pone.0052873.t001
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Table 1.
DNA extraction and genotyping of SNPs in the 5p13.1
region
Genomic DNA was isolated from peripheral blood leukocytes
by standard procedures using the DNA blood mini kit from
Qiagen (Hilden, Germany). The SNPs rs4495224 and rs7720838
on chromosome 5p13.1, for which significant associations with CD
were found in a previous study [21], were genotyped by PCR and
melting curve analysis using a pair of fluorescence resonance
energy transfer (FRET) probes in a LightCycler 480 system
(Roche Diagnostics, Mannheim, Germany), using a similar
methodology as described previously [8,11]. The results of melting
curve analysis were confirmed by analyzing samples representing
all possible genotypes using sequence analysis. All sequences of
primers and FRET probes and primer annealing temperatures
used for genotyping and for sequence analysis are given in Tables
S1 and S2.
In the U.S. American cohort, SNPs rs4532399, rs11955354,
rs11957215, rs7720838, and rs10440635 in the 5p13.1 region were
genotyped using the Human Omni1-Quad chip (Illumina, Inc.,
San Diego, CA). In the German replication cohort, SNPs
rs7720838 and rs10941508 (surrogate marker for rs4495224) in
the 5p13.1 region were genotyped using the SNPlex technology
(Applied Biosystems) in an automated laboratory setup and all
process data were written to and administered by a database-
driven laboratory information management system.
Genotyping of variants in NOD2, IL23R, ATG16L1, and
SLC22A4/5
From previous studies, the genotypes of CD-associated gene
variants in NOD2 [16,17,19], IL23R [8], ATG16L1 [11] and
SLC22A4/5 [32] were available for the German discovery study
cohort. Genotyping of the NOD2 variants p.Arg702Trp
(rs2066844), p.Gly908Arg (rs2066845), and p.Leu1007fsX1008
(rs2066847) as well as analysis of the 1672 CRT SNP in SLC22A4
(rs1050152) encoding OCTN1 and the –207 GRC SNP
(rs2631367) in SLC22A5 encoding OCTN2 were performed by
PCR and restriction fragment length polymorphism analysis as
described previously [32]. The primer sequences, the restriction
enzymes used and the resulting fragment lengths are given in
Table S3. The 10 CD-associated IL23R SNPs (rs1004819,
rs7517847, rs10489629, rs2201841, rs11465804,
rs11209026=p.Arg381Gln, rs1343151, rs10889677, rs11209032,
rs1495965) described by Duerr and co-workers [7] and nine
ATG16L1 SNPs (rs13412102, rs12471449, rs6431660, rs1441090,
rs2289472, rs2241880 (=p.Thr300Ala), rs2241879, rs3792106,
rs4663396) described by Hampe and co-workers [9] were
genotyped by PCR and melting curve analysis as described
previously [8,11]. All sequences of primers and FRET probes and
primer annealing temperatures used for genotyping and for
sequence analysis are given in Tables S4 and S5.
In the U.S. American cohort, ATG16L1 SNPs rs13412102,
rs3828309, rs2289474, rs2241880 (=p.Thr300Ala), and
rs2241879 were genotyped using the Human Omni1-Quad chip
(Illumina, Inc.). In the German replication cohort, ATG16L1 SNPs
rs13412102, rs12471449, rs6431660, rs1441090, rs2289472,
rs2241880 (=p.Thr300Ala), rs2241879, rs3792106, rs4663396
were genotyped using the SNPlex technology (Applied Biosys-
tems). Since genotyping was performed in the IBD centers in
which the blood samples were centrally collected, each IBD center
used its own ‘‘in house’’ genotyping protocol (Munich: PCR and
melting curve analysis using a pair of FRET probes; Kiel: SNPlex
technology (Applied Biosystems); Pittsburgh: Human Omni1-
Quad chip (Illumina, Inc.)). Given the differences in the
genotyping platforms, not all SNPs were identical; therefore,
surrogate markers with high linkage disequilibrium were used
where appropriate.
In silico analysis of transcription factor binding sites
SNPs rs4495224 and rs7720838 were analyzed for potential
human transcription factor binding sites applying the online tool
TFSEARCH which is based on the TRANSFAC database [33].
Transcription factors with predicted binding scores of $75 for
each allele were included in the analysis (max. score=100). For
each SNP, major and minor alleles including the flanking 15
nucleotides upstream (59) and downstream (39) were analyzed.
Statistical analyses
Data were evaluated by using the SPSS 13.0 software (SPSS
Inc., Chicago, IL, U.S.A.) and R-2.4.1. (http://cran.r-project.org).
Each genetic marker was tested for Hardy-Weinberg equilibrium
in the control population. Fisher’s exact test was used for
comparison between categorical variables, while Student’s t test
was applied for quantitative variables. Single-marker allelic tests
were performed with Pearson’s x
2 test. All tests were two-tailed,
considering p-values,0.05 as significant. Odds ratios were
calculated for the minor allele at each SNP. For multiple
comparisons, Bonferroni correction was applied where indicated.
Interactions between different polymorphisms were tested using
the –epistasis option provided in PLINK (http://pngu.mgh.
harvard.edu/,purcell/plink/).
Results
The SNPs rs4495224 and rs7720838 in the 5p13.1 region
are significantly associated with Crohn’s disease
In all three subgroups (CD, UC, and controls) of the German
discovery study cohort, the allele frequencies of the SNPs
rs4495224 and rs7720838 were in accordance with the predicted
Hardy-Weinberg equilibrium and are summarized in Table 2.
Similar to the results of the study of Libioulle et al. (D9=0.84)
[21], both PTGER4 expression-modulating SNPs were in linkage
disequilibrium (controls: D9=0.843; CD: D9=0.795; UC:
D9=0.871; all cohorts: D9=0.836).
Overall, significant differences in the frequencies of rs4495224
and rs7720838 were observed in CD patients compared to healthy
controls (Table 2), identifying SNP rs4495224 and rs7720838 as
significantly CD-associated genetic variants. In the CD group, the
frequency of the rarer C allele of the rs4495224 polymorphism was
0.28, whereas in the controls it was 0.34 (p=4.10610
25, OR 0.76
[0.67–0.87]). The frequencies of the minor G allele of the
rs7720838 polymorphism were 0.375 in CD and 0.43 in the
controls (p=6.91610
24, OR 0.81 [0.71–0.91]), suggesting a
protective effect of the minor allele in CD. In contrast, no
associations were observed in UC patients. In UC, the frequencies
of the rs4495224 C allele and of the rs7720838 G allele were 0.35
(p=3.17610
21, OR 1.08 [0.93–1.26]) and 0.45 (p=2.75610
21,
OR 1.09 [0.94–1.26]), respectively. However, the lack of
association with UC could be related to a lack of power. In a
power analysis using the Genetics Power Calculator (http://pngu.
mgh.harvard.edu/,purcell/gpc/), we used the settings unselected
controls and, a minor allele frequency of 43%. Considering our
sample size of 471 UC cases and 1488 controls, our study had
25% power for detecting differences in the minor allele frequencies
between cases (UC) and controls corresponding to an OR of 1.10.
PTGER4 in Crohn’s Disease
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the PTGER4 region were strongly associated with CD susceptibil-
ity (Table 3). The SNPs rs4532399, rs11955354 and rs11957215,
which were in nearly complete linkage disequilibrium according to
the data of the Human HapMap project, were used as surrogate
markers for SNP rs4495224. The minor allele frequencies of all
these three SNPs were 0.28 in the North American CD cohort and
0.35 the in the North American control population (rs4532399:
p=3.07610
26; 0.72 [0.62–0.82], rs11955354: p=5.45610
26;
0.72 [0.63–0.83], rs11957215: p=7.08610
26; 0.72 [0.63–0.83]).
The frequencies of the minor G allele of the SNP rs7720838 were
0.375 in CD and 0.45 in the controls (p=2.19610
27; 0.71 [0.62–
0.81]). For the SNP rs10440635, which is a surrogate marker for
rs7720838, the minor allele frequencies were 0.36 in the CD
cohort and 0.45 in the control population (p=8.60610
28; 0.70
[0.61–0.80]).
In the German replication cohort, the SNP rs10941508, which
was in nearly complete linkage disequilibrium within the data of
the Human HapMap project and served as surrogate marker for
rs4495224, was also strongly associated with CD susceptibility.
The frequencies of the minor G allele of the SNP rs10941508 were
0.30 in the CD population and 0.34 in the controls
(p=8.60610
28; 0.70 [0.61–0.80]) (Table 4).
Genotype-phenotype analyses
So far, the phenotypic consequences of gene variants in the
5p13.1 region are unknown. We therefore performed a detailed
genotype-phenotype correlation in the German IBD discovery
cohort for which detailed phenotype data were available. In CD
patients, the analysis revealed no significant associations of the
SNPs rs4495224 and rs7720838 with phenotypic characteristics
such as age, male-to-female-ratio, body mass index (BMI), family
history, incidence of stenoses and fistulas, use of immunosuppres-
sive agents, or extraintestinal manifestations (Table S6 and S7).
Weak associations with disease onset ,16 years in CD patients
heterozygous for SNP rs4495224 (p=0.036) and with less colonic
involvement according to the Montreal classification [31] in
heterozygous carriers of the rs7720838 variant compared to the
wildtype patients (p=0.023) did not fulfill the significance criteria
after Bonferroni correction (Table S6 and S7). Similarly, in UC,
no significant associations between these SNPs and the main
disease characteristics were found after Bonferroni correction
(Table S8 and S9).
Analysis for epistasis between the 5p13.1 region and
other CD susceptibility genes
Next, potential epistasis between the SNPs in the 5p13.1 region
and other, replicated CD-associated gene variants was analyzed.
This analysis included the three common NOD2 variants
p.Arg702Trp, p.Gly908Arg, and p.Leu1007fsX1008, 10 recently
identified CD-associated IL23R variants [7,8] 9 variants in
ATG16L1 [9,11] and SLC22A4/5 gene variants [32]. After
Bonferroni correction, no evidence for epistasis between SNPs in
the 5p13.1 region and gene variants in NOD2, IL23R,o r
SLC22A4/5 was found (data not shown). In contrast, marked
epistasis between the two SNPs of the 5p13.1 region (rs4495224
and rs7720838) and SNPs within the ATG16L1 gene was
demonstrated in the German CD discovery cohort (Table 5).
The interactions were particularly strong between rs7720838 and
ATG16L1 polymorphisms, with p values ranging from 7.81610
23
to 1.09610
27 (Table 5). Strong interactions of rs7720838 occurred
with rs13412102 in the 59-flanking region (p=1.09610
27), with
Table 2. Allele frequencies of the SNPs rs4495224 and rs7720838 in German discovery population of patients with Crohn’s disease
and ulcerative colitis and controls.
Gene Minor Crohn’s disease Ulcerative colitis Controls
marker allele n=844 n=471 n=1488
MAF p value OR [95% CI] MAF p value OR [95% CI] MAF
rs4495224 C 0.28 4.10610
25 0.76 [0.67–0.87] 0.35 3.17610
21 1.08 [0.93–1.26] 0.34
rs7720838 G 0.38 6.91610
24 0.81 [0.71–0.91] 0.45 2.75610
21 1.09 [0.94–1.26] 0.43
Note: Minor allele frequencies (MAF), allelic test p-values, and odds ratios (OR, shown for the minor allele) with 95% confidence intervals (CI) are shown.
doi:10.1371/journal.pone.0052873.t002
Table 3. Allele frequencies of the SNPs within the 5p13.1 region in North American replication cohort.
Gene marker Gene/region Minor allele Crohn’s disease Controls
n=684 n=1440
MAF p value OR [95% CI] MAF
rs4532399* 5p13.1 A 0.28 3.07610
26 0.72 [0.62–0.82] 0.35
rs11955354* 5p13.1 A 0.28 5.45610
26 0.72 [0.63–0.83] 0.35
rs11957215* 5p13.1 G 0.28 7.08610
26 0.72 [0.63–0.83] 0.35
rs7720838 5p13.1 C 0.37 2.19610
27 0.71 [0.62–0.81] 0.45
rs10440635
& 5p13.1 G 0.36 8.60610
28 0.70 [0.61–0.80] 0.45
Note: Minor allele frequencies (MAF), allelic test p-values, and odds ratios (OR, shown for the minor allele) with 95% confidence intervals (CI) are shown.
*surrogate markers for rs4495224;
&surrogate marker for, rs7720838.
doi:10.1371/journal.pone.0052873.t003
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27) and with
rs2241880 (p.Thr300Ala) in the central region of ATG16L1
(p=5.99610
27; Table 5). In the German CD discovery cohort,
the epistasis between ATG16L1 and rs4495224 was also strong, but
less pronounced than that of rs7720838; the strongest interaction
with rs4495224 involved rs6431660 (p=8.37610
25) and the
coding SNP rs2241880 (p.Thr300Ala) (p=3.81610
24; Table 5).
In addition, the ATG16L1 SNP rs2241879, which was associated
with CD in several studies [9–11], displayed strong interactions
with both 5p13.1 SNPs (rs7720838: p=1.10610
26, rs4495224:
p=3.07610
24).
Despite the pronounced epistasis between ATG16L1 and the
5p13.1 region regarding CD susceptibility in the German
discovery cohort, no significant epistatic effect of these genetic
regions on the CD or UC phenotype could be detected after
Bonferroni correction (Table S8 and S9) which was partly related
to the great number of interactions tested for (n=189 for CD;
n=144 for UC).
To analyze if the epistasis between the 5p13.1 region and
ATG16L1 could be replicated in other CD populations, we
investigated a U.S. American and a German CD replication
cohort. In the U.S. American cohort, both 5p13.1 (Table 3) and
ATG16L1 (Table S10) were strongly associated with CD suscep-
tibility. Using different genotyping platforms (Human Omni1-
Quad chip from Illumina in the U.S. American and SNPlex
technology from Applied Biosystems in the German replication
cohort), a slightly different panel of SNPs in the 5p13.1 region and
ATG16L1 SNPs was available (Tables 3 and 4, Table S11). In the
U.S. American study population, rs4532399 in the 5p13.1 region
served as surrogate marker for rs4495224, and rs2289474 was
used as surrogate marker for rs6431660. In the German
replication cohort, rs10941508 in the 5p13.1 region served as
surrogate marker for rs4495224. However, as shown in Tables S12
and S13, there was no significant epistasis detected between these
gene markers, suggesting that the strong epistasis between 5p13.1
and ATG16L1 found in the German CD discovery cohort is not a
general phenomenon in Caucasian CD populations.
Analysis of potential transcription factor binding sites in
the 5p13.1 region harboring SNPs rs4495224 and
rs7720838
The study of Libioulle et al. analyzed the influence of 26 SNPs
within the gene desert on chromosome 5p13.1 regarding PTGER4
gene expression [21]. They found that, amongst all analyzed
SNPs, the CD risk alleles in rs4495224 and rs7720838 were most
strongly associated with increased PTGER4 expression [21].
However, the underlying mechanisms explaining of how these
SNPs might influence PTGER expression, were not examined so
far. We therefore analyzed in silico for potential transcription factor
binding sites in the genomic sequences containing SNPs rs4495224
or rs7720838 and the respective surrounding nucleotides. As
depicted in table 6, several predicted transcription factor binding
sites with high binding scores could be identified for the CD risk
alleles in rs4495224 and rs7720838, suggesting a stronger
transcription factor binding and hence higher expression of the
neighboring PTGER4 gene as it has been described by Libioulle et
al. [21] for the respective CD risk alleles.
Interestingly, rs4495224 is part of a nearly perfect NF-kB
consensus sequence (with only one nucleotide not matching the
consensus sequence; Table 6). Accordingly, the highest binding
scores for the DNA sequence containing the CD risk allele were
predicted for the transcription factor NF-kB (p50/p65 heterodi-
mer) as well as for the NF-kB subunits NF-kB p65 (RelA), NF-kB2
(p52) and c-Rel (Table 6). Binding of these factors to DNA
containing the protective allele was predicted to be considerably
weaker suggesting lower transcriptional activation of neighboring
genes.
For rs7720838, the IBD-associated transcription factor XBP1,
that has recently been identified as important modulator of
intestinal inflammation [34], was predicted to bind strongly to a
DNA sequence with the CD risk allele while predicted binding to a
sequence with the protective allele was substantially lower
(Table 6).
Table 4. Allele frequencies of the SNPs within the 5p13.1 in German replication cohort with Crohn’s disease patients and controls.
Gene marker Gene/region Minor allele Crohn’s disease Controls
n=1098 n=1048
MAF p value OR [95% CI] MAF
rs10941508
1 5p13.1 G 0.30 1.96610
23 0.82 [0.72–0.93] 0.34
Note: Minor allele frequencies (MAF), allelic test p-values, and odds ratios (OR, shown for the minor allele) with 95% confidence intervals (CI) are shown.
1surrogate marker for rs4495224.
doi:10.1371/journal.pone.0052873.t004
Table 5. Epistasis analysis between SNPs rs4495224 and
rs7720838 in the 5p13.1 region and SNPs within the ATG16L1
gene regarding CD susceptibility in the German discovery
study population.
5p13.1/PTGER4 SNPs
ATG16L1 SNPs rs4495224 rs7720838
P value P value
rs13412102 4.84610
24 1.09610
27
rs12471449 1.09610
22* 1.39610
22*
rs6431660 8.37610
25 2.29610
27
rs1441090* 8.36610
22* 5.66610
22*
rs2289472 3.05610
24 1.34610
26
rs2241880 (Thr300Ala) 3.81610
24 5.99610
27
rs2241879 3.07610
24 1.10610
26
rs3792106 2.65610
24 1.40610
25
rs4663396* 9.86610
23* 7.81610
23*
Note:
*All p values given are uncorrected for multiple comparisons. After applying
Bonferroni correction, all associations remained significant (p,0.05) with the
exceptions of those marked with an asterisk.
doi:10.1371/journal.pone.0052873.t005
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In summary, our study confirms the 5p13.1 region as
susceptibility locus in CD. This finding is in agreement with the
genome-wide association studies by Libioulle and co-workers [21]
and Franke et al. [35]. In contrast, we could not replicate a
contribution of the 5p13.1 region to UC susceptibility which was
demonstrated by recent meta-analyses of GWAS [29,36] and may
be related to the limited sample size of our cohort and the weaker
effect of the 5p13.1 region on UC susceptibility compared to CD
susceptibility. Very recently, the largest meta-analysis ever
performed in IBD, including more than 75,000 cases and controls,
demonstrated an association with UC, which convincingly
confirms that there is a very strong association of the PTGER4
locus with CD (p=1.81610
282), while there is only a weak
association with UC (p=1.68610
25 for the immunochip UC
cohort) which reached only in all UC cohorts combined genome-
wide significance (p=1.36610
210 for all UC cohorts combined)
[37]. This clearly illustrates that extremely large cohorts are
required to show significant results for weak associations as for
PTGER4 and UC. Following Bonferroni correction, we could not
identify a specific IBD subphenotype associated with the
investigated SNPs in the 5p13.1 region.
In CD, the observed ORs for the minor alleles of the analyzed
PTGER4 SNPs are below a value of 1.0 and thus, are most likely
protective while the major alleles represent the CD risk alleles for
Table 6. Analysis of transcription factor binding sites in the DNA sequences surrounding SNPs rs4495224 and rs7720838 applying
the program TFsearch.
rs4495224 (approx. 200 kb upstream of PTGER4):
59-CAGAGTTTAAATTGG[A/C]ACTTCCCCTGAGGAC-39 plus strand
39-GTCTCAAATTTAACC[T/G]TGAAGGGGACTCCAG-59 minus strand
Transcription factor Consensus sequence
#(59R39) DNA strand
Position
relative to SNP
(59R39)
Binding score
risk allele
{
Binding score
protective allele
{
NF-kB (p50/p65 heterodimer) GGGAMTTYCC minus 27t o+2 92.2 86.0
c-Rel SGGRNWTTCC minus 27t o+2 89.3 82.6
NF-kB p65 (RelA) GGGRATTTCC minus 27t o+2 88.7 78.8
NF-kB2 (p52) NGGGACTTTCCA minus 28t o+3 86.3 79.1
MZF1 NGNGGGGA plus +4t o+11 82.6 82.6
Elk-1 NNNACMGGAAGTNCNN minus 212 to +3 80.5 80.5
STATx TTCCCRKAA plus +3t o+11 79.8 79.8
SRY AAACWAM minus +8t o+14 77.3 77.3
Tst-1 NNKGAWTWANANTKN minus 27t o+7 77.1 68.8
HSF2 NGAANNWTCK plus 22t o+7 76.3 67.3
HSF1 RGAANTRRCN plus 22t o+7 75.7 65.2
p300 NNNRGGAGTNNNNS minus 29t o+4 73.3 77.2
rs7720838 (approx. 193 kb upstream of PTGER4):
59-CAGGGCTTTGACATG[T/G]CATCACCAATGCATC-39 plus strand
39-GTCCCGAAACTGTAC[A/C]GTAGTGGTTACGTAG-59 minus strand
Transcription factor Consensus sequence
# (59R39) DNA strand
Position
relative to SNP
(59R39)
Binding score
risk allele
{
Binding score
protective allele
{
GATA-1 SNNGATNNNN minus 27t o+2 85.3 88.6
XBP-1 NNGNTGACGTGKNNNWT minus 26t o+10 83.2 73.3
GATA-2 NNNGATRNNN minus 27t o+2 80.6 83.0
Oct-1 CWNAWTKWSATRYN minus 27t o+6 79.6 73.5
CREB NNGNTGACGYNN minus 29t o+2 79.5 82.8
C/EBPb RNRTKNNGMAAKNN minus 28t o+5 78.6 79.2
C/EBP NNTKTGGWNANNN minus 212 to 0 78.5 80.8
MZF1 NGNGGGGA minus 210 to 23 77.4 77.4
c-Myc/Max NANCACGTGNNW minus 24t o+7 77.3 64.1
Note:
#Nucleotides in the genomic sequences according with the consensus sequences are underlined and the polymorphic nucleotide is marked in bold.
{Predicted binding scores differing more than 5 points between CD risk alleles and protective alleles are depicted in bold. Scores differing 10 points and more are
depicted in bold italic. Binding score threshold for each allele was set to 75.0. Nucleotide codes: K=G or T, M=A or C, R=A or G, S=C or G, W=A or T, Y=C or T, N=A,
G, C or T.
doi:10.1371/journal.pone.0052873.t006
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(=major alleles) were associated with increased PTGER4
expression in the study of Libioulle et al. [21]. Although protective
functions of EP4 against inflammation have been described, [22–
24,38], other studies reported a proinflammatory role for EP4 in
models of rheumatoid arthritis or experimental autoimmune
encephalitis [39–41]. Interestingly, EP4 has been shown to drive
the differentiation of Th1 cells and proliferation of Th17 [40–42].
Since these two proinflammatory T cell subsets play very
important roles in the pathogenesis of CD [43], increased
expression of PTGER4 and therefore increased EP4 signaling in
carriers of the CD risk alleles of the two SNPs rs4495224 and
rs7720838 is plausible. The transcription factors NF-kB and XBP1
were identified as very likely candidates for binding to the
respective genomic regions and thereby increasing PTGER4
expression. NF-kB is a transcription factor involved in many
inflammatory signaling pathways and has been implicated in the
pathogenesis of IBD [44]. XBP1 has very recently been described
as an important transcription factor that links endoplasmatic
reticulum stress to the development of intestinal inflammation
[34]. However, further functional studies are necessary to clarify
the influence of these transcription factors on PTGER4 expression
and to further elucidate the role of this chromosomal region in the
CD pathogenesis.
Prostaglandins are arachidonic acid metabolites produced by
the action of the enzymes cyclooxygenase-1 and -2 (COX-1 and
COX-2) which have been identified to play a crucial role in the
physiological regulation of inflammation and gastrointestinal
homeostasis [45–47] as well as in the defense of the intestinal
mucosa [48]. Moreover, a haplotype of prostaglandin synthase 2/
cyclooxygenase 2 has been found to be involved in IBD
susceptibility [25] and microsomal prostaglandin E synthase-1 is
overexpressed in IBD [26]. Interestingly, prostaglandin 15-deoxy-
delta(12,14)-PGJ2 attenuates the development of intestinal injury
caused by dinitrobenzene sulphonic acid (DNBS) in rats [27].
Recently, PTGER4 polymorphisms have been found to be
associated with asthma [49] including aspirin-intolerant asthma
[50], suggesting a role also in inflammation of the respiratory tract.
Prostaglandin E2-EP4 signaling was further found to play a key
role in skin immune responses by promoting migration and
maturation of Langerhans cells, specialized antigen-presenting
cells (APCs) [51]. Since APCs such as dendritic cells (DCs) are
critical for the defense against intestinal bacterial microbiota [52],
prostaglandin E2-EP4 signaling might also contribute to IBD via
the regulation of intestinal DCs. Interestingly, we and others
demonstrated that the capacity of lamina propria DCs to form
transepithelial dendrites for sampling of luminal antigens depends
on the chemokine receptor CX3CR1 [52] which was identified by
us as an important genetic modifier of the CD phenotype [13].
In addition, we report strong epistasis between PTGER4
expression-modulating SNPs in the 5p13.1 region and the
ATG16L1 gene in the German discovery cohort. Based on the p-
value of 1610
27 for the strongest interaction (between rs7720838
and rs13412102), this is the strongest epistasis signal reported so
far and nearly 3-log fold stronger than the most significant gene-
gene interaction reported in the meta-analysis by Barrett et al.
[53]. However, this gene-gene interaction was only observed in the
German discovery population but not in the U.S. American and
the German replication cohorts, suggesting that the epistasis
between the two gene regions is not a general phenomenon
contributing to CD susceptibility in all Caucasian populations.
This is supported by the recent meta-analyses of GWAS [35,53]
which did not find epistasis between SNPs in the PTGER4 and
ATG16L1 regions.
The lack of replication of the gene-gene interaction between
PTGER4 and ATG16L1 regions may be related to population
differences, although this is unlikely given the close genetic
similarity between the South and North German population
representing the discovery and the replication cohort, respectively.
However, some minor genetic differences were shown between the
populations analyzed in this study (e.g., association of CD with
DLG5 only in the North German population [54,32] and
association with PHOX2B, NCF4 and FAM92B only in the North
American population [10] but not the German population [55]).
Furthermore, methodological issues could explain the lack of
replication of the gene-gene interaction between PTGER4 and
ATG16L1 since a different genotyping platform was used in the
U.S. American and in the German CD replication cohorts
requiring the use of surrogate markers instead of the original SNPs
used in the German discovery population. However, given the
high linkage disequilibrium between original SNPs and surrogate
markers, this is very unlikely. The observed gene-gene interaction
could also be coincidental which illustrates the need for extremely
large sample sizes to find convincing association evidence and
separate true signals from noise for complex trait loci that have
small effect sizes.
The potential intergenic interaction between ATG16L1 and the
5p13.1 region would be of particular interest since the exact
functional consequences of polymorphisms in the 5p13.1 chromo-
somal region are largely unknown. In the study of Libioulle and
co-workers [21], the disease-associated alleles were found to
correlate with expression levels of PTGER4 which was the gene
located closest to the associated region. The finding of PTGER4 as
an important CD target gene in the 5p13.1 region is also in line
with reports of Ptger4 knock-out mice developing severe DSS-
induced colitis [22,23].
In summary, our study confirms the chromosome 5p13.1 region
asa susceptibilitylocusinCD.Forthefirsttime,wedemonstratethe
strongly CD-associated PTGER4SNPsrs4495224 andrs7720838as
part of binding sites for NF-kB and XBP1, suggesting that these
transcription factors may modulate PTGER4 expression. However,
further functional assays are necessary to clarify if the SNPs
analyzed in our study modulate binding of transcription factors and
thereby regulating PTGER4 expression and IBD susceptibility. We
could not identify a specific IBD phenotype associated with the
SNPs rs4495224 and rs7720838, although the cohort used in this
study convincingly demonstrated other strong association such as
for the NOD2 variant p.Leu1007fsX1008 with ileal CD involve-
ment, stenosis and need for surgery [16,17,56,57], suggesting that
the sample size in CD was sufficient to detect clinically relevant
associations. In addition, a strong epistasis signal between
rs4495224 and rs7720838 with SNPs in the ATG16L1 gene region
was observed in the German CD discovery cohort. However, this
gene-gene interaction could not be replicated in the North
American CD cohort and in the German CD replication cohort,
arguing against a major role of this interaction in the CD
pathogenesis. Further functional studies are required to clarify the
exact role of the 5p13.1 region in the CD pathogenesis.
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